Perrigo (PRGO)

Executive Summary

Perrigo Company plc is a leading global provider of self-care and generic pharmaceuticals, headquartered in Dublin, Ireland. With a history dating back to 1887, the company specializes in over-the-counter (OTC) products, store-brand drugs, and infant nutrition. Perrigo operates with a mission to deliver affordable health and wellness solutions through a robust supply chain and formulation expertise, serving consumers primarily via private label and branded products. As a public company listed on the NYSE under ticker PRGO, Perrigo has a market capitalization of approximately $1.57 billion and continues to navigate a competitive generic drug landscape. In recent years, Perrigo has focused on streamlining operations, improving margins, and expanding its OTC store brand portfolio. The company faces headwinds including pricing pressure in generics and supply chain disruptions, but benefits from strong demand for affordable healthcare options. Key catalysts include potential FDA approvals for pending abbreviated new drug applications (ANDAs), strategic acquisitions to bolster its product line, and margin improvements from cost optimization initiatives. While the company's pipeline appears mature with mostly completed bioequivalence studies, near-term growth may be driven by retail partnerships and new product launches in the self-care segment.

Upcoming Catalysts (preview)

• Q2 2026FDA approval of high-value ANDAs (e.g., generic versions of branded drugs)70% success
• Q1 2026Q1 2026 earnings report with margin improvement and revenue guidance85% success
• Q3 2026Strategic acquisition or partnership in OTC store brands50% success